Fig. 4

Buformin regulates AMPK/mTOR and RTK signaling pathways in erbB-2-overexpressing breast cancer cells. SKBR3 and BT474 cells were treated with buformin (0, 0.1, 0.3, 1, or 3 mM) for 24 h. Expression and activation/phosphorylation of the indicated proteins relating to the AMPK/mTOR (a) and RTK (b) pathways were analyzed using Western blotting